21调查｜谁在收割阿尔茨海默病患者钱包？

Core Viewpoint - The market for GV-971 (also known as "Jiuyiqi"), a drug for Alzheimer's disease, is experiencing disruptions due to reports of its production halt, leading to a surge in demand for alternative products labeled as "GV-971" in the market [1][5][8]. Group 1: Market Dynamics - Reports indicate that the production of GV-971 has been temporarily halted, causing a supply shortage in pharmacies across the country [5][6]. - The price of GV-971 on e-commerce platforms has skyrocketed from its original price of 296 yuan per box to around 1000 yuan, with many listings having purchase limits [5][6]. - There is a growing trend of individuals attempting to sell their remaining stock of GV-971 at high prices on social media, reflecting the urgent demand from families of Alzheimer's patients [5][6]. Group 2: Product Misrepresentation - A number of products claiming to be "GV-971" are being marketed as food and health products, which do not have the same therapeutic effects as the actual drug [3][8]. - Many of these products are sold under the guise of "medicine-food homology," which is misleading as these products do not possess the same medicinal properties as GV-971 [8][11]. - Some sellers are using terms like "Beijing Tongrentang" to enhance credibility, despite these products not being officially authorized by the brand [3][8]. Group 3: Regulatory Concerns - The sale of GV-971 as a prescription drug is regulated, and any unauthorized resale is illegal, posing risks of counterfeit or substandard products entering the market [5][11]. - The distinction between actual pharmaceuticals and food products is critical, as the latter cannot replace the therapeutic functions of prescribed medications [11][12]. - The active ingredient in GV-971, derived from marine brown algae, is not included in the list of substances that can be classified as "medicine-food homology," further complicating the market situation [11][12].